We are live on ! Find out more

FRNM

Freenome Inc

FRNM

Market cap $1.69B

15.75 USD

-0.24

1.5%

At close Updated Sep 9, 4:00 PM EDT

1 day

-1.5%

5 days

3.35%

1 month

35.54%

3 months

21.06%

6 months

21.06%

Year to date

21.06%

1 year

21.06%

5 years

21.06%

10 years

21.06%

About: Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. It is developing a range of blood-based cancer screening tests.

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to SimpleScreen™ Lung, the company's investigational lung cancer screening test.

FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test

FDA approves Freenome's blood test for colorectal cancer screening

The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the U.S. this fall, ‌the companies said on Monday.

FDA approves Freenome's blood test for colorectal cancer screening

FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening – BRISBANE, Calif. and ABBOTT PARK, Ill.

FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

See News Rankings

Price charts implemented using Lightweight Charts™